Astellas Pharma has withdrawn the marketing application for its venous thromboembolism preventative darexaban in Japan, the first market in which it had filed the drug.
The marketing application, which was submitted in late September 2010, had been seeking approval of the oral Factor Xa direct inhibitor for the prevention of venous thromboembolism (VTE) in patients at risk, such as those undergoing orthopaedic surgical procedures in the lower limbs.
via pmlive.com
No comments:
Post a Comment